Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Infectious Disease Reports
Special Issues
Viral Hepatitis: Epidemiological Features and Prevention
share announcement

Special Issue "Viral Hepatitis: Epidemiological Features and Prevention"

A special issue of Infectious Disease Reports (ISSN 2036-7449). This special issue belongs to the section "Viral Infections".

Deadline for manuscript submissions: 31 October 2023 | Viewed by 6945

Special Issue Editor

Dr. George Rachiotis

E-Mail Website
Guest Editor
Department of Hygiene and Epidemiology, Medical Faculty, University of Thessaly, Larissa 41222, Greece
Interests: epidemiology; occupational medicine; social determinants of health

Special Issue Information

Dear Colleagues,

COVID-19 is dominating global scientific interest today, but other diseases still remain a considerable public health threat at a global scale. The disease related to viral hepatitis is one of these, the burden of which is increasing. Five years ago, the Member States of the World Health Organization committed to eliminating viral hepatitis as a public health threat by 2030, with a particular focus on hepatitis B and hepatitis C virus infection. However, global viral hepatitis elimination by 2030 seems highly unlikely now. It is for this reason that this Special Issue of Infectious Diseases Reports entitled “Viral Hepatitis: Epidemiological Features and Prevention” is being launched, and we are look forward to receiving your submissions. You are welcome to send short proposals for submissions of feature papers to our Editorial Office for evaluation.

Dr. George Rachiotis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Infectious Disease Reports is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Epidemiology
  • Prevention
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E
  • Occupational and environmental risk factors

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

get_app
Article
Noncompliance with Therapeutic Guidelines for Chronic Hepatitis B Patients in Minas Gerais, Brazil
by
Cristiane Faria Oliveira Scarponi
,
Marco Antônio Ferreira Pedrosa
,
Marcos Paulo Gomes Mol
and
Dirceu Bartolomeu Greco
Infect. Dis. Rep. 2022, 14(6), 955-966; https://doi.org/10.3390/idr14060094 - 28 Nov 2022
Viewed by 950
Abstract
Standardized treatment regimens for chronic hepatitis B (CHB) are crucial in suppressing viral replication, disease progression and the development of complications. However, information on routine compliance with such therapeutic recommendations in medical practice is rare. Aim: To evaluate the application of Brazilian therapeutic [...] Read more.
Standardized treatment regimens for chronic hepatitis B (CHB) are crucial in suppressing viral replication, disease progression and the development of complications. However, information on routine compliance with such therapeutic recommendations in medical practice is rare. Aim: To evaluate the application of Brazilian therapeutic guidelines for CHB within the scope of the Unified Health System in Minas Gerais state. Four key recommendations from the national guidelines were compared with data from treated patients: (i) eligibility to start treatment; (ii) type of treatment applied; (iii) rescue antiviral therapy; and (iv) monitoring of virological response. Most physicians (69.8%) declared to adopt these guidelines, while 10 of them were unaware. However, according to the criteria established by the guidelines, only 39.5% of treated patients should have been considered “truly” eligible to start treatment and only 67.6% of these underwent the recommended pharmacological treatment. The virological response was laboratory monitored in just over a third of patients. Rescue therapy was adequately supplanted in 41.2% of patients previously treated with lamivudine. There was low compliance with national guidelines by public service physicians in Brazil, highlighting the need to raise awareness of the importance of its adherence to expand the control of CHB. Thus, increasing the adherence of health professionals to this tool is a current challenge for health institutions and managers. Full article
(This article belongs to the Special Issue Viral Hepatitis: Epidemiological Features and Prevention)
►▼ Show Figures

Figure 1

get_app
Article
The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya
by
Francis Mugeni Wanyama
,
Rudolf Tauber
,
Alfred Mokomba
,
Catherine Nyongesa
and
Véronique Blanchard
Infect. Dis. Rep. 2022, 14(3), 433-445; https://doi.org/10.3390/idr14030047 - 07 Jun 2022
Cited by 2 | Viewed by 1638
Abstract
Ovarian cancer (OC) is a gynecological malignancy characterized by high morbidity and mortalities due to late-stage diagnosis because accurate early diagnostic biomarkers are lacking. Testing of Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections in OC patients [...] Read more.
Ovarian cancer (OC) is a gynecological malignancy characterized by high morbidity and mortalities due to late-stage diagnosis because accurate early diagnostic biomarkers are lacking. Testing of Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections in OC patients is pertinent in light of the emerging evidence of their contribution to poor prognosis. We, for the first time, investigated the prevalence of HBV, HCV, and HIV infections in a Kenyan cohort of OC to inform optimal management. We recruited a cohort of women above 18 years of age, comprising 86 OC patients and 50 healthy controls. Participants’ blood samples were serologically screened for HBV, HCV, and HIV. We found seroprevalence rates of 29.1%, 26.7%, and 1.2% for HBV, HIV, and HCV, respectively, in OC patients. The healthy control group had HBV and HIV seroprevalence rates of 3.9% for each with no positive HCV case. HBV/HIV coinfection was noted only in the OC group with a positivity rate of 17.4%. In summary, we found higher HBV and HIV seroprevalence in Kenyan OC patients compared to the healthy control group, whereas HCV prevalence was reflective of the general population. Hence, we recommend screening for HBV and HIV among OC patients destined for anticancer treatment. Full article
(This article belongs to the Special Issue Viral Hepatitis: Epidemiological Features and Prevention)
►▼ Show Figures

Figure 1

Other

Jump to: Research

get_app
Brief Report
Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report
by
Maria Pokorska-Śpiewak
,
Anna Dobrzeniecka
and
Agnieszka Ogrodnik
Infect. Dis. Rep. 2022, 14(4), 574-578; https://doi.org/10.3390/idr14040061 - 03 Aug 2022
Viewed by 1193
Abstract
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end [...] Read more.
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treatment. No adverse effects were reported during or after the treatment, and the compliance was good. Decisions on starting treatment in children below 6 years of age should be made individually, taking compliance into consideration. The adjustment of formulation and dosing of medication during treatment is necessary in young children. Further research with larger groups of patients is needed to confirm our findings. Full article
(This article belongs to the Special Issue Viral Hepatitis: Epidemiological Features and Prevention)
get_app
Brief Report
Reported Barriers to Hepatitis C Treatment among Pregnant and Early-Parenting Mothers Undergoing Substance Use Disorder Treatment in One U.S. State
by
Ayooluwatomiwa Deborah Adekunle
,
Kathi L. Harp
,
Zaynab G. Al-Abdali
,
Agatha S. Critchfield
,
Sheila Barnhart
and
Kathleen T. Winter
Infect. Dis. Rep. 2022, 14(1), 1-11; https://doi.org/10.3390/idr14010001 - 22 Dec 2021
Viewed by 2495
Abstract
Nationwide, the prevalence of the hepatitis C virus (HCV) has risen in recent years. At least 90% of infected persons must be treated to achieve global elimination targets. The current study aimed to explore barriers to, and facilitators of, direct-acting antiviral (DAA) HCV [...] Read more.
Nationwide, the prevalence of the hepatitis C virus (HCV) has risen in recent years. At least 90% of infected persons must be treated to achieve global elimination targets. The current study aimed to explore barriers to, and facilitators of, direct-acting antiviral (DAA) HCV treatment uptake amongst pregnant and early-parenting women undergoing comprehensive substance use treatment. Twenty participants with documented HCV antibody positivity were recruited from two substance use treatment centers in central Kentucky. Semi-structured interviews were conducted to explore knowledge about HCV, previous experiences, and intentions to seek care. Themes were extracted using an inductive analytical approach. Most participants were aware of the dangers posed by HCV infection. However, there was a high degree of misinformation about transmission mechanisms and treatment eligibility requirements. Low priority for HCV treatment also surfaced as a barrier to treatment uptake. Participants reported being unable to seek care due to time and resource limitations in the presence of a highly demanding treatment process. Findings from the current study suggest that more work is needed to eliminate residual barriers that limit access to HCV treatment among pregnant and early-parenting women in treatment for substance use disorder. Full article
(This article belongs to the Special Issue Viral Hepatitis: Epidemiological Features and Prevention)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop